Navigation Links
Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
Date:9/30/2009

TSX Venture: QPT

EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (TSX:PLB) ("Paladin").

The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumor antigens that are presented in a variety of cancers. The first and most advanced of these product candidates is Oregovomab, an anti-CA125 antibody for the treatment of ovarian cancer patients that Quest will evaluate in combination with front-line chemotherapy.

Quest also acquired anti-MUC1, anti-TAG72, anti-PSA and anti-CA19.9 antibodies that could potentially be used for the treatment of breast, lung, stomach, colorectal, pancreas and prostate cancer.

"We believe that these newly acquired immunotherapeutic antibody products have the opportunity to become significantly more effective when combined with chemotherapy, radioimmuno therapy or photodynamic therapy," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "As one of the original inventors of this technology, I have a deep understanding of the potential of these compounds to become more efficacious treatments for cancer when used as an adjunct in combination with these established therapies. We intend to expeditiously evaluate the potential of the acquired products for conducting a registration trial for one or more combination therapies, which, if successful, could lead directly to one or more applications for regulatory approval."

As part of the transaction, Paladin receives an upfront payment of $37,500 and 1.5 million common shares of Quest, with an additional 1.5 million common shares to be issued to Paladin on or before December 31, 2010. Paladin may also receive an additional 2
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 “Nature has developed, very cleverly, ... we desire in optical design,” said Joseph Shaw, director ... “As we explore surfaces and structures at the nanoscale, ... presented in San Diego in August during a conference ... ” chaired by Shaw and Rongguang Liang of the ...
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... September 16, 2014 CIRTEC Medical Systems’ ... Highley as CEO of CIRTEC. , “I am ... for the Company.” noted Brian Highley. “The company has ... sustaining strong organic growth over the past two years. ... continuing to improve and expand the services Cirtec offers ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the leading ... products to hospitals, physician office laboratories and alternate ... October 1, 2014, it will serve as Siemens ... market segments and as a semi-exclusive sales distributor ... contiguous United States . LABSCO ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:9/16/2014)... neuroscientists have discovered the "molecular brakes" that time the ... of mice. These "hair cells" translate sound waves into ... are interpreted as sounds. If the arrangement of the ... summary of the research will be published in ... "The proteins Hey1 and Hey2 act as brakes to ...
(Date:9/16/2014)... own bacterial identity. That,s the conclusion of University of ... the genetic fingerprints of bacteria on 57 species of ... demonstrates for the first time that host plants from ... very different microbial communities on their leaves," said lead ... the UO,s Institute of Ecology and Evolution who is ...
(Date:9/16/2014)... bacteria, and their environment is becoming ever more ... Sullivan, associate professor in the University of Arizona,s ... Hallam from the University of British Columbia in ... nutrient and energy cycles that power the earth," ... are the environments these bacteria live in, and ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3
... the University of Iowa Carver College of Medicine have ... a defective protein, which is the most common cause ... inherited disease caused by mutations in a gene that ... and cellular location, this protein, cystic fibrosis transmembrane conductance ...
... diamond-back moth. It lays its eggs on the cabbage plants ... However, Morten Emil Mldrup from the University of Copenhagen has ... his spectacular research results at a public PhD defense on ... cheat the diamond-back moths to lay their eggs on tobacco ...
... summarize research papers that have been recently published in ... (JGR-D), Journal of Geophysical Research-Space Physics (JGR-A), ... Journal of Geophysical Research-Oceans (JGR-C). In this ... river catchments, 2. Atmospheric CO2 drove climate change during ...
Cached Biology News:Gene network restores CF protein function 2Gene technology helps deceive greedy pest insects 2AGU journal highlights -- 31 July 2012 2AGU journal highlights -- 31 July 2012 3AGU journal highlights -- 31 July 2012 4AGU journal highlights -- 31 July 2012 5AGU journal highlights -- 31 July 2012 6AGU journal highlights -- 31 July 2012 7AGU journal highlights -- 31 July 2012 8AGU journal highlights -- 31 July 2012 9AGU journal highlights -- 31 July 2012 10
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: